https://www.selleckchem.com/products/gsk864.html
There have been no comprehensive large-scale studies that have evaluated the benefits of chemotherapy-based regimens in addressing -altered advanced non-small-cell lung cancer (NSCLC) in a first-line setting. Data on alteration subtypes and concomitant alterations are also limited. Accordingly, our retrospective, real-world POLISH study assesses the efficacy of first-line chemotherapy alone (C) as well as combinations with immune checkpoint inhibitors (C + I) or angiogenesis inhibitors (C + A) for -altered NSCLC; molecular features are a